CTX001 not checked

Cajal Therapeutics Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“CTX001 administered orally at the assigned cohort dose once daily for 29 days.”In the company’s words, NCT07901933 on ClinicalTrials.gov
Tested for
Chronic Kidney Disease, Anemia
Main trialPhase 1
“This is a Phase 1b, randomized, double-blinded, placebo-controlled study of CTX001 in participants with anemia and chronic kidney disease who are not on dialysis.”In the company’s words, NCT07901933 on ClinicalTrials.gov

Other drugs for Chronic Kidney Disease

All 79 drugs for Chronic Kidney Disease

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting Oct 2027 Study of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow CTX001

Following is part of Solo: you see every change to CTX001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in